Replies to post #172507 on Biotech Values

[oc631]

Are you saying that the two directors are resigning one day early in order to make a bigger stink about the whole affair?

That's not what I was suggesting yet it's not outside the realm of possibilities. The fact they are leaving is the issue here. My point was made to counter your suggestion that ENTA was trying to avoid bad press and the attention of corporate-governance watchdog groups.

How does a disagreement about selling the company wash with the statement in ENTA’s 8-K filing that the resignations are “not the result of any disagreement with Enanta on any matter relating to its operations, policies or practices” (http://www.sec.gov/Archives/edgar/data/1177648/000119312514008032/d658819d8k.htm )? Is your opinion that the 8-K statement fails to rule out a disagreement with respect to M&A because M&A is not explicitly mentioned?

Yes. It's my opinion M&A dealings fall outside the parameters of the 8-K release. I would not consider this part of normal day-to-day operations which the key sentence (above) points to. That's my opinion. There's enough legal wiggle room to support this idea.